Exelixis traded at $22.27 this Tuesday July 5th, increasing $0.70 or 3.25 percent since the previous trading session. Looking back, over the last four weeks, Exelixis gained 18.58 percent. Over the last 12 months, its price rose by 21.10 percent. Looking ahead, we forecast Exelixis to be priced at 20.99 by the end of this quarter and at 19.33 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,862.00 24.00 0.63% 4.80%
Eisai 6,167.00 342.00 5.87% -41.24%
Acadia Pharmaceuticals 15.27 0.90 6.26% -36.72%
Agios Pharmaceuticals 25.45 2.09 8.95% -55.55%
Akebia Therapeutics 0.41 0.02 5.14% -88.35%
Amgen 246.73 1.18 0.48% 1.26%
AstraZeneca 11,004.00 204.00 1.89% 27.10%
Bayer 56.26 0.74 1.33% 10.38%
Bluebird Bio 5.05 0.77 17.99% -83.73%
BioMarin Pharmaceutical 86.36 1.38 1.62% 2.12%
Bristol-Myers Squibb 75.96 -0.88 -1.15% 13.97%
Cytokinetics 43.90 2.90 7.07% 124.78%
Esperion Therapeutics 6.99 0.54 8.37% -64.80%
Exelixis 22.27 0.70 3.25% 21.10%
Genmab 2,419.00 12.00 0.50% -9.67%
Glaxosmithkline 43.30 -0.45 -1.03% 8.09%
Immunogen 4.90 0.29 6.29% -21.60%
Incyte Corp 79.25 1.58 2.03% -4.91%
Ionis Pharmaceuticals 37.85 -0.21 -0.55% -3.76%
Eli Lilly 327.18 2.47 0.76% 38.98%
MacroGenics 3.31 0.26 8.52% -88.38%
Merck & Co 92.64 0.22 0.24% 18.60%
Moderna Inc 155.54 5.59 3.73% -33.34%
Mirati Therapeutics 71.96 0.78 1.10% -56.07%
Neurocrine Biosciences 98.30 -0.95 -0.96% 0.87%
Nektar Therapeutics 3.93 0.18 4.80% -76.76%
Novartis 81.33 0.42 0.52% -4.28%
Puma Biotechnology 2.66 -0.12 -4.32% -69.43%
Pfizer 51.64 -0.67 -1.28% 31.43%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Seattle Genetics 176.77 -3.34 -1.85% 15.91%
Sanofi 50.18 -0.83 -1.63% -2.43%
Xencor 30.45 1.59 5.51% -11.84%

Indexes Price Day Year
USND 11322 194.39 1.75% -22.79%
US2000 1741 13.57 0.79% -23.44%
US400 2293 -2.92 -0.13% -14.44%

Exelixis
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.